Oncology Consultations®: Critical Conversations Between MPN Centers of Excellence and the Community

Release Date: January 15, 2021
Expiration Date: January 15, 2022

Activity Overview

This Oncology Consultations^® is a video-based program in which 2 experts use a case-based approach to discuss the treatment and management of myeloproliferative neoplasms (MPNs). In this activity, the faculty focus on diagnosis, assessment, and management of patients with myelofibrosis and polycythemia vera. This engaging format is designed to help clinicians identify best practices in the diagnosis and management of MPNs and to improve outcomes for their patients with these diseases.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Incyte Corporation.

Target Audience

This educational activity is directed toward hematologists, medical oncologists, nurse practitioners, nurses, nurse navigators, and fellows who treat patients with MPNs. Physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of MPNs will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss key approaches for risk stratification among patients with MPNs
• Apply clinical trial evidence to manage clinical scenarios encountered in the management of patients with MPNs
• Evaluate methods to address challenges in the management of MPNs, and identify opportunities for clinical trial participation among patients with these malignancies
• Outline strategies in community practice settings to coordinate care for long-term disease monitoring and adverse event management so that optimized outcomes can be achieved among patients with MPNs

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

John Mascarenhas, MD
Director, Adult Leukemia Program
Leader of Clinical Investigation, Myeloproliferative Disorders Program
Tisch Cancer Institute
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Grant Research Support: Arog Pharmaceuticals, CTI BioPharma, Incyte Corporation, Hoffmann-La Roche, Novartis Pharmaceuticals, Merck & Co., Janssen Pharmaceuticals, ProMedica; Consultant: Hoffmann-La Roche, Celgene Corporation, Prelude Therapeutics, ProMedica, Constellation Pharmaceuticals.

Sophie D. Morse, MD, MSc
Carol G. Simon Cancer Center
Overlook Medical Center
Summit, NJ

Disclosures: Sophie D. Morse, MD, MSc, has no relevant financial relationships with commercial interests.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.